We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Pilot Study of a Dendritic Cell Vaccine in HIV-1 Infected Subjects (PARC002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00833781
Recruitment Status : Completed
First Posted : February 2, 2009
Results First Posted : March 8, 2016
Last Update Posted : March 8, 2016
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of the study is to find out whether an experimental autologous dendritic cell vaccine is safe, well tolerated, and whether it can strengthen the immune system's response to HIV.

Condition or disease Intervention/treatment Phase
HIV-1 Infection HIV Infections Biological: mRNA-transfected autologous dendritic cells Biological: autologous dendritic cells with no mRNA transfection Phase 1 Phase 2

Detailed Description:
This is a randomized trial to evaluate whether mRNA-transfected dendritic cell vaccination is safe and immunogenic in HIV-infected participants who are on antiretroviral therapy.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Pilot, Double-blind, Placebo-controlled, Randomized Clinical Trial of mRNA-transfected Autologous Dendritic Cells in Subjects With Well-controlled Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy
Study Start Date : August 2009
Primary Completion Date : December 2013
Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Active Comparator: mRNA-transfected dendritic cells
Participants in this arm/group received mRNA-transfected autologous dendritic cells
Biological: mRNA-transfected autologous dendritic cells
Injections will be administered intradermally at weeks 0, 2, 6 and 10.
Placebo Comparator: Dendritic cells without mRNA
Participants in this arm/group received autologous dendritic cells with no mRNA transfection
Biological: autologous dendritic cells with no mRNA transfection
Injections will be administered intradermally at weeks 0, 2, 6 and 10.
Other Name: Autologous dendritic cells not transfected with mRNA.


Outcome Measures

Primary Outcome Measures :
  1. Safety of the DC Vaccine (as Measured by Frequency of Adverse Events) [ Time Frame: After vaccination ]
    Number of participants with grade 3 or 4 adverse events related to vaccination

  2. Change From Baseline to Week 14 in ELISPOT Response to Gag and Nef [ Time Frame: Baseline and 14 weeks ]
    Immunogenicity was measure by interferon gamma enzyme-linked immunospot (ELISPOT) assay. The number of spot forming cells per million PBMC was determined at each time point. The fold ratio represents week 14 value divided by value at baseline.


Secondary Outcome Measures :
  1. T Cell Proliferation [ Time Frame: Baseline to week 14 ]
  2. IL2 and IFN Gamma Production [ Time Frame: Baseline to week 14 ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HIV-1 positive
  • CD4+ T Cell count >200
  • Undetectable HIV viral load for 6 months prior to screening
  • On antiretroviral treatment for 12 months prior to screening

Exclusion Criteria:

  • Hepatitis C positive
  • Detectable HIV viral load within 6 months prior to study entry
  • Females who are pregnant or nursing
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00833781


Locations
United States, Massachusetts
Infectious Disease Unit; Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Institute of Allergy and Infectious Diseases (NIAID)
Investigators
Principal Investigator: Rajesh Gandhi, MD Massachusetts General Hospital
More Information

Publications:
Responsible Party: Rajesh T. Gandhi, MD, Director of Education, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00833781     History of Changes
Other Study ID Numbers: 2008p001577
R01AI066992-04 ( U.S. NIH Grant/Contract )
DAIDS-ES ID 10731 ( Other Identifier: DAIDS )
First Posted: February 2, 2009    Key Record Dates
Results First Posted: March 8, 2016
Last Update Posted: March 8, 2016
Last Verified: March 2016

Keywords provided by Rajesh T. Gandhi, MD, Massachusetts General Hospital:
HIV vaccine
Dendritic cells
treatment experienced

Additional relevant MeSH terms:
Infection
Communicable Diseases
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases